Filing Flows › Foghorn Therapeutics (FHTX) › Q2 2025
Foghorn Therapeutics (FHTX) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 5, 2025
Foghorn Therapeutics (FHTX) reported revenue of $7.6M for the second quarter 2025 (Q2 2025), +10% from a year earlier and +27% from the quarter before. Operating margin was -279.2%, net loss $17.9M (237.3% of revenue).
Foghorn Therapeutics, Q2 2025: revenue $7.6M (+10% year over year), operating margin -279.2%, net loss $17.9M, operating cash flow −$21.0M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $7.6M | +27% | +10% |
| Operating profit | −$21.1M | — | — |
| Net earnings | −$17.9M | — | — |
| Operating cash flow | −$21.0M | — | — |
What changed
Revenue was $7.6M in Q2 2025, up 10% year over year and up 27% from the previous quarter.
Operating costs exceeded revenue by $21.1M, an operating margin of -279.2%. Total costs fell 15% while revenue rose 10%. The quarter ended with a net loss of $17.9M, narrower than the previous quarter's $18.8M loss.
Operating cash flow was −$21.0M. Non-cash charges added back $900K of depreciation and amortization and $2.7M of share-based compensation. Working capital and other items used $6.7M. Capital expenditures of $22K exceeded it, leaving free cash flow of −$21.0M.
Questions
What was Foghorn Therapeutics' revenue in the second quarter 2025?
Foghorn Therapeutics (FHTX) reported revenue of $7.6M for the second quarter 2025 (Q2 2025), +10% from a year earlier and +27% from the quarter before.
Was Foghorn Therapeutics profitable in the second quarter 2025?
Operating loss was $21.1M (-279.2% of revenue) and net loss $17.9M.